Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 290

1.

Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics.

Slobodova Z, Ehrmann J, Krejci V, Zapletalova J, Melichar B.

Neoplasma. 2011;58(3):189-97.

PMID:
21391734
[PubMed - indexed for MEDLINE]
2.

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.

J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.

PMID:
12529347
[PubMed - indexed for MEDLINE]
Free Article
3.

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Christiaens MR, Vergote I.

Breast Cancer Res Treat. 2005 May;91(1):81-7.

PMID:
15868434
[PubMed - indexed for MEDLINE]
4.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
[PubMed - indexed for MEDLINE]
5.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
[PubMed - indexed for MEDLINE]
Free Article
6.

Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.

Azizun-Nisa, Bhurgri Y, Raza F, Kayani N.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.

PMID:
19256737
[PubMed - indexed for MEDLINE]
Free Article
7.

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK.

Clin Cancer Res. 1998 Jan;4(1):7-12.

PMID:
9516946
[PubMed - indexed for MEDLINE]
Free Article
8.

Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.

Bandić D, Juretić A, Sarcević B, Separović V, Kujundzić-Tiljak M, Hudolin T, Spagnoli GC, Cović D, Samija M.

Croat Med J. 2006 Feb;47(1):32-41.

PMID:
16489695
[PubMed - indexed for MEDLINE]
Free PMC Article
9.
10.

Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.

Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F.

Virchows Arch. 2010 Oct;457(4):467-76. doi: 10.1007/s00428-010-0964-y. Epub 2010 Aug 31.

PMID:
20809337
[PubMed - indexed for MEDLINE]
11.

Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.

Wilder RB, Curcio LD, Khanijou RK, Eisner ME, Kakkis JL, Chittenden L, Agustin J, Lizarde J, Mesa AV, Macedo JC, Ravera J, Tokita KM.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):799-803. doi: 10.1016/j.ijrobp.2009.08.081.

PMID:
20869583
[PubMed - indexed for MEDLINE]
12.

Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.

el-Ahmady O, el-Salahy E, Mahmoud M, Wahab MA, Eissa S, Khalifa A.

Anticancer Res. 2002 Jul-Aug;22(4):2493-9.

PMID:
12174951
[PubMed - indexed for MEDLINE]
13.

A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma.

Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, King BL, Haffty BG.

Cancer. 2003 Oct 15;98(8):1587-95.

PMID:
14534873
[PubMed - indexed for MEDLINE]
Free Article
14.

Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.

Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P.

Breast Cancer Res Treat. 2009 May;115(2):349-58. doi: 10.1007/s10549-008-0110-6. Epub 2008 Jul 16.

PMID:
18629635
[PubMed - indexed for MEDLINE]
15.

Application of quantitative analysis to biologic profile evaluation in breast cancer.

Querzoli P, Ferretti S, Albonico G, Magri E, Scapoli D, Indelli M, Nenci I.

Cancer. 1995 Dec 15;76(12):2510-7.

PMID:
8625078
[PubMed - indexed for MEDLINE]
16.

Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.

Sharif MA, Mamoon N, Mushtaq S, Khadim MT.

J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103. doi: 02.2009/JCPSP.99103.

PMID:
19208313
[PubMed - indexed for MEDLINE]
17.

Increased expression of osteopontin in patients with triple-negative breast cancer.

Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y, Sun J.

Eur J Clin Invest. 2008 Jun;38(6):438-46. doi: 10.1111/j.1365-2362.2008.01956.x. Epub 2008 Apr 30.

PMID:
18452545
[PubMed - indexed for MEDLINE]
18.

c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.

Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A, Schittulli F.

Tumori. 2006 Jul-Aug;92(4):311-7.

PMID:
17036522
[PubMed - indexed for MEDLINE]
19.

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.

Mohammadizadeh F, Naimi A, Rajabi P, Ghasemibasir H, Eftekhari A.

Indian J Med Sci. 2009 Apr;63(4):152-62. doi: 10.4103/0019-5359.50764.

PMID:
19414985
[PubMed - indexed for MEDLINE]
Free Article
20.

Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.

Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.

Cancer Invest. 2008 Aug;26(7):671-9. doi: 10.1080/07357900801891628.

PMID:
18608215
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk